Literature DB >> 27779720

PACE4 regulates apoptosis in human pancreatic cancer Panc‑1 cells via the mitochondrial signaling pathway.

Xiao-Feng Tian1, Guo-Min Huang1, Hong-Liang Zang1, Hong Cao1.   

Abstract

Previous studies have demonstrated the overexpression of paired basic amino acid cleaving enzyme 4 (PACE4) mRNA in prostate cancer tissues. This overexpression is correlated with higher circulating protein levels in certain patients, however, the role of PACE4 in apoptosis and the potential molecular mechanisms of pancreatic cancer remain to be elucidated. The aim of the present study was to investigate the effect and potential molecular mechanisms of PACE4 on apoptosis in the Panc‑1 pancreatic cancer cell line. Cell proliferation was assessed using a Cell Counting Kit‑8 assay. Apoptotic nuclear shrinkage was monitored using Hoechst 33258 staining. Caspase‑3/7 activities were measured using a colorimetric caspase‑glo 3/7 assay. Alterations in protein expression were monitored using Western blot analysis. The results indicated that PACE4 small interfering (si)RNA inhibited cell proliferation and activated caspase‑3/7 activities. In addition, PACE4 siRNA significantly increased apoptosis via the activation of caspase‑3 and the downregulation of anti‑apoptotic proteins, X‑linked inhibitor of apoptosis protein and phosphorylated‑Akt. In addition, the results showed deregulation of the B cell lymphoma‑2 (Bcl‑2)-associated X protein/Bcl‑2 ratio which led to the release of cytochrome c following PACE4 siRNA transfection. In conclusion, PACE4 siRNA may exert antitumor activity through the mitochondrial pathway and is expected to be a promising therapeutic strategy for the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27779720     DOI: 10.3892/mmr.2016.5885

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  Up-regulation of microRNA-135 or silencing of PCSK6 attenuates inflammatory response in preeclampsia by restricting NLRP3 inflammasome.

Authors:  Xiaolan Zhao; Xun Zhang; Zhao Wu; Jie Mei; Lingling Li; Yujue Wang
Journal:  Mol Med       Date:  2021-07-23       Impact factor: 6.354

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.